Exact Sciences Corporation (EXAS) News
StocksNews Articles for EXAS
|Loading, please wait...|
Latest EXAS News From Around the Web
Below are the latest news stories about Exact Sciences Corp that investors may wish to consider to help them evaluate EXAS as an investment opportunity.
The current cancer treatments lack efficiency, and late diagnostics make everything harder. As a matter of fact, experts have been telling us for a long time that early detection is fundamental to have a significant increase in survival rates. The holy grail for early cancer detections could be a blood...
The U.S. Preventive Services Task Force (USPSTF) appears on the verge of expanding colorectal cancer screening to individuals ages 45 to 49, based on its latest draft recommendations. If it does, Exact Sciences Corp. is ready. A study in Cancer Prevention Research demonstrated that the Madison, Wis.-based company's Cologuard multitarget stool DNA test had better than 95% specificity in individuals with nonadvanced precancerous lesions or negative findings on colonoscopy.
Exact Sciences' colorectal cancer screening test demonstrates low false-positive rate for screening, study shows
Exact Sciences ([[EXAS]] +2.7%) has announced data published in Cancer Prevention Research, a Journal of the American Association for Cancer Research, from a study in 816 eligible participants that showed that among average-risk adults between the ages of 45 and 49, Cologuard demonstrated test specificity of 95.2% in participants with...
New Prospective Data Demonstrate Low False-Positive Rate for Screening Average-Risk People Age 45-49 for Colorectal Cancer with Cologuard®
Exact Sciences Corp. (Nasdaq: EXAS) announced data published today in Cancer Prevention Research, a Journal of the American Association for Cancer Research, that expands on foundational clinical study findings to include a key younger population. Study results show that among average-risk adults between the ages of 45 and 49 Cologuard® (mt-sDNA) demonstrated test specificity of 95.2% in participants with non-advanced precancerous lesions or negative findings at colonoscopy and 96.3% in only those with negative colonoscopy findings. These analyses support potential risk mitigation and cost prevention due to unnecessary diagnostic procedures when using Cologuard as a colorectal cancer screening tool in this younger population.
Exact Sciences saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 75 to 85. As you try to find the best stocks to buy and watch, be sure to pay attention to relative price strength. Exact Sciences is now considered extended and out of buy range after clearing a 139.36 buy point in a second-stage cup with handle.
Exact Sciences (EXAS) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Shares of Exact Sciences (NASDAQ: EXAS) were soaring 12% as of 10:49 a.m. EST on Monday. With such an impressive gain today, it's not surprising that Exact Sciences' preliminary results looked really good. The company expects to post fourth-quarter revenue between $464.5 million and $467.5 million.
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company expects to report revenue between $464.5 million and $467.5 million for the fourth quarter ended Dec. 31, 2020.
The coronavirus pandemic will continue to captivate the world in 2021. But it could also provide a boon for some health care stocks working in telemedicine, remote monitoring and testing.
Exact Sciences provided preliminary guidance for its fourth quarter performance as per which, the company expects to exceed consensus revenue estimates. In an SEC filing, Exact Sciences (EXAS) stated that it expects its 4Q overall revenue to beat the FactSet consensus estimate of $427 million. The company also anticipates its screening revenue and precision oncology revenue to top FactSet’s consensus estimates of $230 million and $104 million, respectively. Additionally, it estimates that COVID-19 testing revenue will come in ahead of FactSet’s $92 million consensus forecast. The company disclosed that it has not yet completed the preparation of its financial statements for 4Q or the full year.